116 related articles for article (PubMed ID: 37844446)
1. Targeting MET endocytosis or degradation to overcome HGF-induced gefitinib resistance in EGFR-sensitive mutant lung adenocarcinoma.
Jiao D; Chen Y; Liu X; Tang X; Chen J; Liu Y; Jiang C; Chen Q
Biochem Biophys Res Commun; 2023 Nov; 682():371-380. PubMed ID: 37844446
[TBL] [Abstract][Full Text] [Related]
2. Hepatocyte growth factor reduces sensitivity to the epidermal growth factor receptor-tyrosine kinase inhibitor, gefitinib, in lung adenocarcinoma cells harboring wild-type EGFR.
Yang H; Wang R; Peng S; Chen L; Li Q; Wang W
Oncotarget; 2016 Mar; 7(13):16273-81. PubMed ID: 26919104
[TBL] [Abstract][Full Text] [Related]
3. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
Donev IS; Wang W; Yamada T; Li Q; Takeuchi S; Matsumoto K; Yamori T; Nishioka Y; Sone S; Yano S
Clin Cancer Res; 2011 Apr; 17(8):2260-9. PubMed ID: 21220474
[TBL] [Abstract][Full Text] [Related]
4. miR-1-3p and miR-206 sensitizes HGF-induced gefitinib-resistant human lung cancer cells through inhibition of c-Met signalling and EMT.
Jiao D; Chen J; Li Y; Tang X; Wang J; Xu W; Song J; Li Y; Tao H; Chen Q
J Cell Mol Med; 2018 Jul; 22(7):3526-3536. PubMed ID: 29664235
[TBL] [Abstract][Full Text] [Related]
5. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S
Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
[TBL] [Abstract][Full Text] [Related]
6. Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer.
Wang W; Li Q; Takeuchi S; Yamada T; Koizumi H; Nakamura T; Matsumoto K; Mukaida N; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S
Clin Cancer Res; 2012 Mar; 18(6):1663-71. PubMed ID: 22317763
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.
Mueller KL; Madden JM; Zoratti GL; Kuperwasser C; List K; Boerner JL
Breast Cancer Res; 2012 Jul; 14(4):R104. PubMed ID: 22788954
[TBL] [Abstract][Full Text] [Related]
8. Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.
Takeuchi S; Wang W; Li Q; Yamada T; Kita K; Donev IS; Nakamura T; Matsumoto K; Shimizu E; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S
Am J Pathol; 2012 Sep; 181(3):1034-43. PubMed ID: 22789825
[TBL] [Abstract][Full Text] [Related]
9. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.
Yano S; Wang W; Li Q; Matsumoto K; Sakurama H; Nakamura T; Ogino H; Kakiuchi S; Hanibuchi M; Nishioka Y; Uehara H; Mitsudomi T; Yatabe Y; Nakamura T; Sone S
Cancer Res; 2008 Nov; 68(22):9479-87. PubMed ID: 19010923
[TBL] [Abstract][Full Text] [Related]
10. miR-1/133a and miR-206/133b clusters overcome HGF induced gefitinib resistance in non-small cell lung cancers with EGFR sensitive mutations.
Jiao D; Jiang C; Zhu L; Zheng J; Liu X; Liu X; Chen J; Tang X; Chen Q
J Drug Target; 2021 Dec; 29(10):1111-1117. PubMed ID: 33955799
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET.
Zhou JY; Chen X; Zhao J; Bao Z; Chen X; Zhang P; Liu ZF; Zhou JY
Cancer Lett; 2014 Sep; 351(2):265-71. PubMed ID: 24983493
[TBL] [Abstract][Full Text] [Related]
12. Evidence that depletion of the sorting nexin 1 by siRNA promotes HGF-induced MET endocytosis and MET phosphorylation in a gefitinib-resistant human lung cancer cell line.
Nishimura Y; Takiguchi S; Ito S; Itoh K
Int J Oncol; 2014 Feb; 44(2):412-26. PubMed ID: 24297483
[TBL] [Abstract][Full Text] [Related]
13. TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation.
Okamoto W; Okamoto I; Tanaka K; Hatashita E; Yamada Y; Kuwata K; Yamaguchi H; Arao T; Nishio K; Fukuoka M; Jänne PA; Nakagawa K
Mol Cancer Ther; 2010 Oct; 9(10):2785-92. PubMed ID: 20716641
[TBL] [Abstract][Full Text] [Related]
14. Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation.
Nakade J; Takeuchi S; Nakagawa T; Ishikawa D; Sano T; Nanjo S; Yamada T; Ebi H; Zhao L; Yasumoto K; Matsumoto K; Yonekura K; Yano S
J Thorac Oncol; 2014 Jun; 9(6):775-83. PubMed ID: 24828661
[TBL] [Abstract][Full Text] [Related]
15. Crizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cells.
Chen X; Zhou JY; Zhao J; Chen JJ; Ma SN; Zhou JY
Anticancer Drugs; 2013 Nov; 24(10):1039-46. PubMed ID: 23962905
[TBL] [Abstract][Full Text] [Related]
16. Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation.
Yamaoka T; Ohmori T; Ohba M; Arata S; Kishino Y; Murata Y; Kusumoto S; Ishida H; Shirai T; Hirose T; Ohnishi T; Sasaki Y
Mol Cancer Ther; 2016 Dec; 15(12):3040-3054. PubMed ID: 27612490
[TBL] [Abstract][Full Text] [Related]
17. EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells.
Chang H; Sung JH; Moon SU; Kim HS; Kim JW; Lee JS
Yonsei Med J; 2017 Jan; 58(1):9-18. PubMed ID: 27873490
[TBL] [Abstract][Full Text] [Related]
18. Ephedrae herba stimulates hepatocyte growth factor-induced MET endocytosis and downregulation via early/late endocytic pathways in gefitinib-resistant human lung cancer cells.
Nishimura Y; Hyuga S; Takiguchi S; Hyuga M; Itoh K; Hanawa T
Int J Oncol; 2016 May; 48(5):1895-906. PubMed ID: 26983447
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cells.
Bonine-Summers AR; Aakre ME; Brown KA; Arteaga CL; Pietenpol JA; Moses HL; Cheng N
Cancer Biol Ther; 2007 Apr; 6(4):561-70. PubMed ID: 17495520
[TBL] [Abstract][Full Text] [Related]
20. Tumor-associated Macrophages Mediate Gefitinib Resistance in Lung Cancer through HGF/c-met Signaling Pathway.
Tang X; Chen Y; Jiao D; Liu X; Chen J; Liu Y; Jiang C; Chen Q
Anticancer Agents Med Chem; 2024; 24(1):30-38. PubMed ID: 37957870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
